单剂与多剂米索前列醇用于引产:一项随机对照试验
该随机对照试验于2016年3月至2017年3月比较单剂与最多4剂米索前列醇引产,纳入250例单胎≥37周、胎膜完整、Bishop评分≤6的孕妇,按产次分层。单剂组与多剂组24小时内阴道分娩率无差异(41.7% vs 44.7%,P=.698),单剂组剖宫产率更高(35.8% vs 22.8%,P=.034),但控制混杂因素后治疗组与剖宫产率不再相关。
要点
- 单剂与多剂米索前列醇24小时内阴道分娩率无显著差异(41.7% vs 44.7%,P=.698)。
- 单剂组剖宫产率高于多剂组(35.8% vs 22.8%,P=.034),但多因素回归后该关联消失。
- 作者认为单剂方案是引产的可接受替代方案,尤其适用于经产妇及首剂后Bishop评分>4者。
核心结论
- 单剂米索前列醇方案是引产的可接受替代方案,尤其适用于经产妇和首剂后Bishop评分>4的患者。
研究设计与样本
- 随机对照试验,2016年3月至2017年3月开展,比较单剂与最多4剂米索前列醇,按产次分层随机。
- 纳入单胎妊娠≥37周、胎膜完整、因引产入院且Bishop评分≤6的孕妇,共250例。
- 主要结局为24小时内阴道分娩率;样本量220例基于80%把握度、α=.05、多剂组假设50%在24小时内阴道分娩、检测单剂组增加20%的假设。
主要发现
- 单剂组与多剂组24小时内阴道分娩率无差异(41.7% vs 44.7%,P=.698)。
- 单剂组与多剂组至阴道分娩时间无差异(1187分钟 vs 1321分钟,P=.202)。
- 单剂组剖宫产率高于多剂组(35.8% vs 22.8%,P=.034)。
- 泊松回归控制引产前Bishop评分、产次、孕龄、体重指数、估计胎儿体重、<6 cm人工破膜及Foley球囊放置后,治疗组与剖宫产率不再相关;引产前Bishop评分<4和未产与剖宫产率显著相关。
临床怎么用
- 作者认为单剂方案是引产的可接受替代方案,尤其适用于经产妇及首剂后Bishop评分>4的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Misoprostol is a common agent that is used to ripen the cervix and induce labor, yet there is no clear evidence of the optimal number of doses needed to achieve a higher rate of vaginal delivery. OBJECTIVE: Our primary objective was to compare the rate of vaginal delivery within 24 hours between a 1-dose and a multiple-dose regimen of misoprostol for the induction of labor. STUDY DESIGN: A randomized controlled trial was conducted from March 2016 to March 2017 that compared a single dose to up to 4 doses of misoprostol. Randomization was stratified by parity. Women with a singleton pregnancy ≥37 weeks gestation with intact membranes who had been admitted for labor induction with a Bishop score ≤6 were included. Our primary outcome was the rate of vaginal delivery within 24 hours. Secondary outcomes included time to vaginal delivery, cesarean delivery rate, and maternal and neonatal morbidity. Based on a power of 80%, an alpha of .05, and the assumption that 50% of women in the multiple-misoprostol group would deliver vaginally in 24 hours, a sample size of 220 patients was needed to detect a 20% increase in vaginal delivery rate within 24 hours in the 1-misoprostol group. Continuous variables were compared with the use of the Mann-Whitney test. Categoric variables were compared with the use of the Fisher's exact test. Probability values <.05 were considered statistically significant. RESULTS: Two hundred fifty women were assigned randomly. Demographics and clinical characteristics were similar between groups. In the univariate analysis, there was no difference in the rate of vaginal delivery within 24 hours between the 1-misoprostol group and the multiple-dose group (41.7% vs 44.7%, respectively; P=.698) or time to vaginal delivery (1187 min vs 1321 min, respectively; P=.202). The 1-misoprostol group had a greater cesarean delivery rate (35.8% vs 22.8%; P=.034). In a Poisson regression that controlled for Bishop score before the initiation of oxytocin, parity, gestational age, body mass index, estimated fetal weight, artificial rupture of membrane at <6 cm, and Foley balloon placement, the treatment group was no longer associated with cesarean delivery rate. Instead, a Bishop score of <4 before the initiation of oxytocin and nulliparity were associated significantly with cesarean delivery rate. CONCLUSION: In this first randomized controlled trial in the literature to compare a single with a multiple dosing of misoprostol, we found that the 1-dose regimen is an acceptable alternative for the induction for labor, especially for multiparous women and for patients with a Bishop score >4 after the first dose.
引用
- Pimentel VM, Arabkhazaeli M, Moon JY, et al. Induction of labor using one dose vs multiple doses of misoprostol: a randomized controlled trial. Am J Obstet Gynecol. 2018. PMID: 29614276. doi:10.1016/j.ajog.2018.03.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。